Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 6/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23734278 | 0.85 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1CYP2C19TK1MET | |
| SCHEMBL18858876 | 0.85 | MET (0.39) | SMN1; SMN2ALDH1A1CYP2C19METDAO | |
| SCHEMBL21637955 | 0.85 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1CYP2C19METDAO | |
| SCHEMBL20870266 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1CYP2C19TK1MET | |
| SCHEMBL18080393 | 0.80 | CYP19A1 (0.33) | SMN1; SMN2ALDH1A1CYP2C19MET | |
| SCHEMBL35260 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP2C19TK1GRIN2DGRIN3B | |
| SCHEMBL25824412 | 0.77 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1CYP2C19HTTGAA | |
| SCHEMBL18080373 | 0.76 | SMN1; SMN2 (0.32) | SMN1; SMN2ALDH1A1CYP2C19MET | |
| SCHEMBL24564759 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1CYP2C19TK1MET | |
| SCHEMBL784395 | 0.76 | MAPK1 (0.43) | SMN1; SMN2ALDH1A1TK1METMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | Singular Genomics Systems, Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230227905-A1 | SEQUENCING COMPLEMENTARY POLYNUCLEOTIDES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-11697736-B2 | Silicon containing detectable compounds | Singular Genomics Systems, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230193361-A1 | METHODS AND COMPOSITIONS USEFUL FOR NUCLEIC ACID SEQUENCING | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-22 | — | — | US | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-05 | — | — | US | disclosed |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220389049-A1 | REVERSIBLE TERMINATORS FOR DNA SEQUENCING AND METHODS OF USING THE SAME | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION (VG) | 2022-12-08 | — | — | US | disclosed |
| US-11225688-B2 | Methods for long read sequencing | Singular Genomics Systems, Inc. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11174281-B1 | Modified nucleotides and uses thereof | Singular Genomics Systems, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021216998-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210189481-A1 | METHODS FOR LONG READ SEQUENCING | FIRST-CITIZENS BANK & TRUST COMPANY | 2021-06-24 | — | — | US | disclosed |
| US-10738072-B1 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190352508-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | FIRST-CITIZENS BANK & TRUST COMPANY | 2019-11-21 | — | — | US | disclosed |
| US-9173893-B2 | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections | COCRYSTAL PHARMA, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697736-B2 | Silicon containing detectable compounds | AS3MT, SCLY, NASP | SMN1; SMN2 558/4885ALDH1A1 1169/4885CYP2C19 4157/4885 |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLL, POLQ, POLB | SMN1; SMN2 3588/4885ALDH1A1 1754/4885CYP2C19 3292/4885 |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | SMN1; SMN2 4326/4885ALDH1A1 3416/4885CYP2C19 3579/4885 |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | AS3MT, SCLY, NASP | SMN1; SMN2 558/4885ALDH1A1 1169/4885CYP2C19 4157/4885 |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | SMN1; SMN2 1466/4885ALDH1A1 1423/4885CYP2C19 325/4885 |
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | NUDT1, RNMT, ADAR | SMN1; SMN2 1541/4885ALDH1A1 1149/4885CYP2C19 2677/4885 |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | SMN1; SMN2 1466/4885ALDH1A1 1423/4885CYP2C19 325/4885 |
| US-20220389049-A1 | REVERSIBLE TERMINATORS FOR DNA SEQUENCING AND METHODS OF USING THE SAME | RNGTT, NT5C3B, NSUN2 | SMN1; SMN2 1958/4885ALDH1A1 3508/4885CYP2C19 2150/4885 |
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | SMN1; SMN2 4165/4885ALDH1A1 3268/4885CYP2C19 3791/4885 |
| US-20190352508-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | AS3MT, SCLY, NASP | SMN1; SMN2 558/4885ALDH1A1 1169/4885CYP2C19 4157/4885 |
| US-11174281-B1 | Modified nucleotides and uses thereof | NUDT1, RNMT, ADAR | SMN1; SMN2 1541/4885ALDH1A1 1149/4885CYP2C19 2677/4885 |
| US-10738072-B1 | Nucleotide analogues | NUDT1, POLN, TYMP | SMN1; SMN2 1337/4885ALDH1A1 1629/4885CYP2C19 3362/4885 |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLRMT, RNGTT, MTR | SMN1; SMN2 4165/4885ALDH1A1 3268/4885CYP2C19 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.